Previously, American drugmaker Eli Lilly had sought to stop compounded versions of its diabetes and obesity medications Mounjaro and Zepbound. The FDA is yet to make a decision on the applications.

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

There has been no update from the FTC on its review of the deal since then. Novo Nordisk faces competition from U.S. rival ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Shares of Amgen (NASDAQ:AMGN) rebounded Wednesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. One analyst said the ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Amgen is testing MariTide as a once-monthly shot, making it a promising potential rival to the weekly blockbuster weight-loss injections from Novo Nordisk and Eli Lilly. Tuesday's stock decline lopped ...